NEW YORK – Myriad Genetics said on Monday that its revenues for the three months ended Sept. 30 declined 22 percent year over year.
Total revenues for the period were $145.2 million, down from $186.3 million. It beat the consensus Wall Street estimate of $135.2 million.
The Salt Lake City-based firm is in the process of changing its financial year to match the calendar year and did not identify the quarter ending on Sept. 30.